0639 GMT - Fresenius Medical Care's results should see a positive share-price response on a higher net profit and sales and earnings that topped views, Morgan Stanley analysts say in a note. The German dialysis company's sales and earnings beat was driven by higher demand for is care enablement segment and cost discipline, they say. The company's reiterated full-year outlook for revenue and operating profit and a stable U.S. market treatment growth is a positive, they add. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
May 06, 2025 02:42 ET (06:42 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。